We are building a UK directory of longevity practitioners with clear credential checks and evidence-led information. The first listings will appear only after the required checks are complete.
See how practitioner listings work
UK focus · Evidence-led editorial standards
Practitioner profiles will appear here after we confirm professional registration, practice details, and permission to publish.
01 · Practitioners
We are assembling the founding practitioner cohort. Profiles will be published only after professional credentials and practice details have been checked.
02 · Supplements
We are reviewing compound profiles against published research and regulatory sources. We do not sell supplements. Each published profile should explain the evidence and its limits.
Selected evidence profiles are available below. More will follow as editorial checks are completed.
A direct precursor to NAD+, a coenzyme central to cellular energy production and DNA repair. Mechanistic data is strong; long-duration human trials testing clinical outcomes are still accumulating. This is the compound everyone is selling — we're the ones asking whether the evidence supports the price tag.
NMN is converted to NAD+ in human tissue following oral supplementation — a pathway confirmed across multiple bioavailability studies. Twelve human RCTs have assessed effects including NAD+ blood levels, insulin sensitivity, muscle function, and endurance. Most trials ran 8–16 weeks, which is insufficient to assess long-duration clinical outcomes. The evidence supports the mechanism; it does not yet support most of the marketing claims.
Postbiotic that induces mitophagy. Associated in randomised trials with improvements in muscle function and immune cell health.
Urolithin A is a postbiotic metabolite produced from pomegranate ellagitannins by gut bacteria. Six randomised controlled trials — including landmark work from Amazentis/EPFL — have measured mitophagy markers, muscle endurance, and immune cell function in human participants. Effects are more pronounced in older adults and in individuals with low UA production capacity. This is the strongest human RCT evidence base in the mitophagy-targeting category.
Polyamine linked to autophagy induction in preclinical work. Observational signals for cardiovascular and cognitive endpoints; RCT evidence thinner.
Spermidine is a natural polyamine found in wheat germ, aged cheeses, soybeans, and mushrooms. Preclinical work consistently links it to autophagy induction via inhibition of EP300 acetyltransferase. Human evidence currently rests on observational studies correlating dietary spermidine intake with cardiovascular and cognitive outcomes. Randomised trial evidence is thinner than for NMN or Urolithin A — our full evidence profile is under editorial review pending source verification.
For practitioners
We plan to check professional registration where applicable, relevant memberships and practice details before publishing a profile. The application and re-verification process will be published before listings open.
Questions about the future directory? Email isacreative.contact@gmail.com with a brief note. Please do not send patient information.
03 · Research Hub
Evidence Profiles summarise published research, cite primary sources, and state the limits of the evidence. Clinical review status is shown on each profile.
A postbiotic that induces mitophagy — randomised trials demonstrate improvements in muscle function and immune cell health, with larger effects in untrained adults than athletes.
NAD+ precursor with strong mechanistic rationale and bioavailability data — but long-duration clinical outcome trials are still accumulating and US regulatory status remains unsettled.
Polyamine linked to autophagy induction — preclinical data is extensive, with human observational signals for cardiovascular and cognitive endpoints, but RCT evidence is thinner.